CA2930156C - Curcuphenol compounds for increasing mhc-i expression - Google Patents
Curcuphenol compounds for increasing mhc-i expression Download PDFInfo
- Publication number
- CA2930156C CA2930156C CA2930156A CA2930156A CA2930156C CA 2930156 C CA2930156 C CA 2930156C CA 2930156 A CA2930156 A CA 2930156A CA 2930156 A CA2930156 A CA 2930156A CA 2930156 C CA2930156 C CA 2930156C
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- cell
- use according
- melanoma
- mhc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361906817P | 2013-11-20 | 2013-11-20 | |
| US61/906,817 | 2013-11-20 | ||
| PCT/US2014/066543 WO2015077411A1 (en) | 2013-11-20 | 2014-11-20 | Curcuphenol compounds for increasing mhc-i expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2930156A1 CA2930156A1 (en) | 2015-05-28 |
| CA2930156C true CA2930156C (en) | 2023-11-07 |
Family
ID=52117996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2930156A Active CA2930156C (en) | 2013-11-20 | 2014-11-20 | Curcuphenol compounds for increasing mhc-i expression |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20150147314A1 (https=) |
| EP (2) | EP3071192B1 (https=) |
| JP (4) | JP6560215B2 (https=) |
| CN (1) | CN106456572A (https=) |
| CA (1) | CA2930156C (https=) |
| DK (1) | DK3071192T3 (https=) |
| ES (1) | ES2775577T3 (https=) |
| HU (1) | HUE049301T2 (https=) |
| PL (1) | PL3071192T3 (https=) |
| WO (1) | WO2015077411A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2930156C (en) | 2013-11-20 | 2023-11-07 | Biommune Technologies Inc. | Curcuphenol compounds for increasing mhc-i expression |
| EP3324967A4 (en) * | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
| JP7520013B2 (ja) * | 2018-12-17 | 2024-07-22 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 置換複素環縮合γ－カルボリンの合成 |
| WO2020154811A1 (en) | 2019-01-31 | 2020-08-06 | Cava Healthcare Inc. | Compounds for increasing mhc-i expression and modulating histone deacetylase activity |
| TW202214245A (zh) * | 2020-08-10 | 2022-04-16 | 國立彰化師範大學 | 雙非癌藥物用於製備治療癌症之醫藥組合物的用途 |
| WO2022125339A2 (en) * | 2020-12-07 | 2022-06-16 | The Trustees Of Indiana University | Methods to sensitize cancer cells to immune attack using atractylenolide i |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6261939A (ja) * | 1985-09-10 | 1987-03-18 | Yamanouchi Pharmaceut Co Ltd | クルクフエノ−ル誘導体及びこれを含有する医薬 |
| KR100439425B1 (ko) * | 2001-03-22 | 2004-07-05 | (주)바이오케어 | 잔토리졸을 포함하는 조성물 및 그 용도 |
| KR100571159B1 (ko) * | 2003-06-24 | 2006-04-18 | 박광균 | 항암제로 유발되는 독성의 억제제 및 이를 함유하는항암제 조성물 |
| CA2688570A1 (en) * | 2007-05-31 | 2008-12-04 | F.P.L. Pharma Inc. | Compositions for prevention or treatment of anorexia-cachexia syndrome and uses thereof |
| CA2930156C (en) | 2013-11-20 | 2023-11-07 | Biommune Technologies Inc. | Curcuphenol compounds for increasing mhc-i expression |
-
2014
- 2014-11-20 CA CA2930156A patent/CA2930156C/en active Active
- 2014-11-20 JP JP2016533609A patent/JP6560215B2/ja not_active Expired - Fee Related
- 2014-11-20 EP EP14815145.9A patent/EP3071192B1/en active Active
- 2014-11-20 US US14/548,726 patent/US20150147314A1/en not_active Abandoned
- 2014-11-20 EP EP19216024.0A patent/EP3639815A1/en not_active Withdrawn
- 2014-11-20 DK DK14815145.9T patent/DK3071192T3/da active
- 2014-11-20 CN CN201480072728.3A patent/CN106456572A/zh active Pending
- 2014-11-20 ES ES14815145T patent/ES2775577T3/es active Active
- 2014-11-20 HU HUE14815145A patent/HUE049301T2/hu unknown
- 2014-11-20 PL PL14815145T patent/PL3071192T3/pl unknown
- 2014-11-20 WO PCT/US2014/066543 patent/WO2015077411A1/en not_active Ceased
-
2017
- 2017-01-25 US US15/415,291 patent/US10751296B2/en active Active
-
2019
- 2019-07-18 JP JP2019132434A patent/JP2019196380A/ja not_active Withdrawn
-
2020
- 2020-08-20 US US16/998,072 patent/US11197832B2/en not_active Expired - Fee Related
-
2021
- 2021-04-06 JP JP2021064761A patent/JP7071570B2/ja not_active Expired - Fee Related
- 2021-11-08 US US17/521,674 patent/US12011421B2/en active Active
-
2022
- 2022-05-09 JP JP2022076869A patent/JP2022093724A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN106456572A (zh) | 2017-02-22 |
| DK3071192T3 (da) | 2020-03-16 |
| US20150147314A1 (en) | 2015-05-28 |
| EP3639815A1 (en) | 2020-04-22 |
| HUE049301T2 (hu) | 2020-09-28 |
| CA2930156A1 (en) | 2015-05-28 |
| EP3071192A1 (en) | 2016-09-28 |
| US20200375917A1 (en) | 2020-12-03 |
| PL3071192T3 (pl) | 2020-06-29 |
| JP7071570B2 (ja) | 2022-05-19 |
| JP2021100982A (ja) | 2021-07-08 |
| US10751296B2 (en) | 2020-08-25 |
| JP2022093724A (ja) | 2022-06-23 |
| US20220062195A1 (en) | 2022-03-03 |
| WO2015077411A1 (en) | 2015-05-28 |
| JP2016539129A (ja) | 2016-12-15 |
| ES2775577T3 (es) | 2020-07-27 |
| JP6560215B2 (ja) | 2019-08-14 |
| US11197832B2 (en) | 2021-12-14 |
| US12011421B2 (en) | 2024-06-18 |
| JP2019196380A (ja) | 2019-11-14 |
| EP3071192B1 (en) | 2019-12-18 |
| US20170319508A1 (en) | 2017-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12011421B2 (en) | Curcuphenol compounds for increasing MHC-I expression | |
| US20160137735A1 (en) | Method of treating multiple myeloma using combination therapies based on anti-cs1 antibodies | |
| US12571799B2 (en) | Biomarkers for determining the efficacy of immune checkpoint inhibitors | |
| KR20060134110A (ko) | 초분자 구조체를 포함하는 방법 및 조성물 | |
| CN105658673B (zh) | 新型的具有4个连接的ctl表位的肽 | |
| AU2014227019B2 (en) | Novel peptide having 5 linked CTL epitopes | |
| KR20130008092A (ko) | 암 치료에서 다중약물 내성 억제용 ｐ-당단백질 170에 대한 표적 치료학적 백신 | |
| WO2023077924A1 (zh) | 一种抗胰腺癌的疫苗、及其医药用途 | |
| EP4373844A1 (en) | Alpha-fetoprotein bioconjugates for disease treatment | |
| EP4694912A2 (en) | Use of beta-catenin antagonist and immunomodulator | |
| JP2012508749A (ja) | 多発性骨髄腫治療のためのベンダムスチン、ドキソルビシンおよびボルテゾミブの併用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20191115 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260108 |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260313 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260313 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260420 |